Rosacea clinical trials at UC Health
2 research studies open to new patients
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
open to eligible people ages 18-70
This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression in rosacea. This is a single-site 16-week open label study at University of California, San Diego. The investigators will do this by first measuring serine protease activity and cathelicidin of all subjects. All subjects will receive Ivermectin topical cream and will be instructed on how to apply it daily for 12 weeks. Participants will return for monthly visits during which their clinical symptoms of facial redness and number of facial papules will be scored, and they will have repeat tape stripping. At the end of the study, tape strips will be analyzed to determine serine protease activity of participants at each of their visits and expression of cathelicidin (LL-37) mRNA. The investigators will then look at changes in serine protease activity and LL-37 expression over time, and they will also determine whether or not these changes correlate with disease severity.
open to eligible people ages 18 years and up
The question that the investigators aim to address in this proposal is how the local lipid mediator profiles of ceramides and eicosanoids are altered in cutaneous and ocular rosacea and how antibiotics alter the lipidome. The investigators also seek to understand how the microbiome is changed in those with and without rosacea, and how the microbiome is altered in those with rosacea. Understanding how the lipidome is modulated in rosacea with antibiotic treatment will serve as the first step in targeting therapies toward directly altering the lipidome to reduce inflammation and ultimately reduce the use of antibiotics.
at UC Davis